Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Venetoclax rapidly induces apoptosis and carries a boxed warning for TLS, particularly in patients with high absolute lymphocyte counts, bulky nodes, or impaired renal function. Evidence-based mitigation uses a weekly dose-ramp schedule to gradually debulk disease, combined with pre- and post-dose hydration (oral/IV), uric acid lowering (allopurinol for most; rasburicase for very high risk or elevated baseline uric acid), and electrolyte monitoring. High-risk initiations warrant inpatient observation with labs at ~6–8 hours and 24 hours after each new dose; intermediate risk may be outpatient with intensive monitoring if reliable. Beginning at full dose (Option A) is unsafe. Assuming oral therapy is low risk (Option C) ignores pharmacology. Diuretics alone (Option D) do not prevent urate/phosphate precipitation or hyperkalemia. The APRN operationalizes risk stratification, TLS ordersets, patient education (red flags), and clear criteria to hold or repeat a dose escalation step if labs worsen, working closely with pharmacy and inpatient teams.

Prior mantle/chest radiation before age 30 confers high lifetime breast cancer risk comparable to some hereditary syndromes. Enhanced surveillance is recommended: annual contrast-enhanced breast MRI beginning 8 years after radiation or by age 25 (whichever is later) and addition of annual mammography at age 30. Alternating MRI and mammography every 6 months helps detect interval cancers. MRI detects invasive cancers in dense post-radiation breasts; mammography adds microcalcification detection. Deferring to age 40 (Option A) misses a prolonged high-risk window. Symptom-based screening (Option C) forfeits early detection. Ultrasound (Option D) is not a substitute for MRI/mammography in this population. APRNs coordinate imaging logistics, counsel on breast self-awareness, review reproductive/endocrine history (e.g., prolactin, fertility, pregnancy timing), and discuss risk-reduction strategies such as lifestyle modification and, in select cases, chemoprevention or risk-reducing surgery after genetics evaluation. Ensure prior radiation details are captured in the survivorship plan and communicate with primary care to maintain adherence and follow-up of findings.

Guidelines recommend primary G-CSF prophylaxis when the regimen’s baseline febrile neutropenia (FN) risk is ≥20% or when intermediate risk (10–20%) is compounded by patient-specific factors such as age >65, comorbidities, prior FN, poor nutrition, or open wounds. Docetaxel/cyclophosphamide can approach the high-risk threshold, and this patient’s age and comorbidities increase risk, warranting prophylaxis to maintain dose intensity and reduce hospitalizations. Pegfilgrastim administered ≥24 hours after chemotherapy (or daily filgrastim for several days) lowers FN incidence; patients need counseling on bone pain management, when to call, and access to same-day evaluation. Empiric dose reduction at cycle 1 (Option C) may compromise efficacy in curative-intent therapy. Routine prophylactic oral antibiotics (Option D) are not a substitute for G-CSF and may promote resistance. Waiting for FN to occur (Option A) increases morbidity. APRNs operationalize standing orders for timely growth factor delivery, reinforce fever pathways, and reassess the need for prophylaxis as tolerance becomes evident.

Eligibility for germline testing is driven by tumor features and age—not solely family history. Triple-negative breast cancer diagnosed at age ≤60 meets criteria for germline testing (e.g., BRCA1/2 and other susceptibility genes). Identifying a pathogenic variant informs surgical planning (risk-reducing options), systemic therapy choices (e.g., PARP inhibitors), radiation considerations, and cascade testing for relatives. Tumor-only sequencing (Option D) may detect somatic variants and occasionally suggest germline findings, but it is not a substitute for dedicated germline testing with pre- and post-test counseling. Waiting for ovarian cancer (Option B) misses timely, impactful information. Declining testing due to a negative family history (Option A) ignores the limited sensitivity of pedigree screening, small families, and de novo variants. The APRN coordinates rapid referral to genetics, discusses implications of results, turnaround times relative to treatment decisions, and psychosocial aspects (insurance, disclosure). Document informed consent, manage patient expectations regarding variants of uncertain significance, and plan for modification of therapy based on actionable findings.

Neutropenic sepsis is time critical. Mortality rises with each hour of antibiotic delay. Immediate actions include obtaining blood cultures (peripheral and from any central line), measuring lactate, initiating broad-spectrum antipseudomonal coverage within 60 minutes, and aggressive crystalloid resuscitation (≈30 mL/kg) with reassessment of perfusion. Add MRSA coverage (e.g., vancomycin) when indicated—hemodynamic instability, catheter infection, pneumonia, or severe mucositis. Early source control (e.g., drainage) and vasopressors for persistent hypotension follow established sepsis bundles. Deferring antibiotics for imaging (Option A) or cultures (Option D) is unsafe. Monotherapy with vancomycin (Option B) lacks gram-negative and Pseudomonas coverage. APRN responsibilities include activating sepsis/neutropenic fever pathways, rapid triage, allergy verification, dose adjustments for organ dysfunction, and early consultation with infectious diseases. Continuous monitoring, daily de-escalation based on culture data, and growth-factor support in select patients complete the initial management bundle.